Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Ines Nicoletti

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|June 11, 2002
Small molecules in anti-angiogenic therapyRaffaella Giavazzi, Maria Ines Nicoletti
Molecular Cancer Therapeutics|February 27, 2004
Gene expression correlating with response to paclitaxel in ovarian carcinoma xenograftsMaria Rosa Bani, Maria Ines Nicoletti, Nawal W Alkharouf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2003
The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopicallyAngela Garofalo, Elitza Naumova, Luigi Manenti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivativeGiulia Taraboletti, Gianluca Micheletti, Monica Rieppi, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Current Opinion in Investigational Drugs (London, England : 2000)|June 11, 2002
Small molecules in anti-angiogenic therapyRaffaella Giavazzi, Maria Ines Nicoletti
Molecular Cancer Therapeutics|February 27, 2004
Gene expression correlating with response to paclitaxel in ovarian carcinoma xenograftsMaria Rosa Bani, Maria Ines Nicoletti, Nawal W Alkharouf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2003
The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopicallyAngela Garofalo, Elitza Naumova, Luigi Manenti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivativeGiulia Taraboletti, Gianluca Micheletti, Monica Rieppi, et al.
Pageof 1